Inmune Bio (INMB) Net Cash Flow (2018 - 2025)
Historic Net Cash Flow for Inmune Bio (INMB) over the last 8 years, with Q3 2025 value amounting to -$5.6 million.
- Inmune Bio's Net Cash Flow fell 30067.71% to -$5.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$5.4 million, marking a year-over-year increase of 3213.03%. This contributed to the annual value of -$15.2 million for FY2024, which is 638.52% up from last year.
- Latest data reveals that Inmune Bio reported Net Cash Flow of -$5.6 million as of Q3 2025, which was down 30067.71% from $14.9 million recorded in Q2 2025.
- Inmune Bio's Net Cash Flow's 5-year high stood at $45.0 million during Q3 2021, with a 5-year trough of -$13.1 million in Q4 2024.
- Over the past 5 years, Inmune Bio's median Net Cash Flow value was -$3.4 million (recorded in 2022), while the average stood at $1.3 million.
- As far as peak fluctuations go, Inmune Bio's Net Cash Flow surged by 233869.73% in 2021, and later crashed by 77432.08% in 2024.
- Quarter analysis of 5 years shows Inmune Bio's Net Cash Flow stood at -$9.8 million in 2021, then soared by 41.77% to -$5.7 million in 2022, then decreased by 3.97% to -$5.9 million in 2023, then plummeted by 121.75% to -$13.1 million in 2024, then surged by 57.11% to -$5.6 million in 2025.
- Its Net Cash Flow stands at -$5.6 million for Q3 2025, versus $14.9 million for Q2 2025 and -$1.5 million for Q1 2025.